… growth factor (EGF) belongs to a family of related peptides (EGF-like growth factor), which
include transforming growth factor o (TGFo… EGF-like growth factors bind to activate one or more …

… from tissue resected 68 days after the initiation of erlotinib treatment, after the patient was
off study and no longer treated with erlotinib. There was not sufficient tissue to complete all …

… Erlotinib (Tarceva®) has demonstrated a survival benefit in … erlotinib, epidermal growth
factor receptor (EGFR) protein expression may provide a basis for selecting patients for treatment …

… cell carcinoma; erlotinib; gefitinib; and epidermal growth factor receptor were combined with
… cell lung; Iressa; gefitinib; ZD1839; Tarceva; erlotinib; OSI774; and EGFR-TK. These terms …

… Besides mutations in the EGFR gene that make the target sensitive to gefitinib and erlotinib
treatment, it has been shown that other mutations in the EGFR gene are associated with …

… Most adverse events associated with erlotinib plus gemcitabine treatment in this study
were mild-to-moderate, consistent with previous studies [2-5]. Rash was more frequent with …

… Recurrent cancer was noted in 40 patients, four while receiving erlotinib treatment and 36
after stopping erlotinib (Appendix Table A1, online only). The median time to recurrence after …

… In this study, we investigated the effect of erlotinib treatment on autophagy in 4 NSCLC cell
lines with different EGFR mutation status, in order to understand the possible mechanisms …

… of rash during treatment with the epidermal growth factor receptor inhibitor erlotinib and
improved … (single agent in non–small-cell lung cancer, n = 444 in erlotinib group and n = 229 in …

… Erlotinib (Tarceva) is an orally available HER1 (epidermal growth factor receptor, EGFR)
tyrosine kinase inhibitor advancing through clinical trials for the treatment of a range of human …